A PHASE 2, SINGLE CENTER, OPEN-LABEL, MULTIPLE DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DAILY SUBCUTANEOUSLY ADMINISTERED ELX-02 IN PATIENTS WITH NEPHROPATHIC CYSTINOSIS BEARING ONE OR MORE CTNS GENE (CYSTINOSIN) NONSENSE MUTATIONS
- Registry ID
- EL-003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ELOXX PHARMACEUTICALS INC
- Start date
- 2019-07-29
- Last update
- 2019-05-30
Conditions
View on source registry